Komal Jhaveri, Medical Oncologist and Clinical Researcher of Breast Medicine and Early Drug Developments, Section Head of Endocrine Therapy, Breast Medicine Service, and Clinical Director of Early Drug Development Service at Memorial Sloan Kettering Cancer Center, shared Mirrors of Medicine’s post on X, adding:
“DB-08 provided safety data for various strategic combinations including TDXd + ET, certainly relevant as we can use them in the residual disease setting for triple positive breast cancer.”
Quoting Mirrors of Medicine‘s post:
“DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer
The phase Ib DESTINY-Breast08 study assessed trastuzumab deruxtecan (T-DXd) combinations in HER2-low metastatic breast cancer, establishing recommended phase II doses with capecitabine, capivasertib, anastrozole, and fulvestrant. Objective response rates ranged from 40% to 71.4% across cohorts. Grade ≥3 adverse events were common but manageable, and interstitial lung disease occurred in some patients.
Overall, T-DXd combinations demonstrated encouraging preliminary efficacy with safety profiles consistent with known toxicities.”
Title: DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer
Authors: Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid, Carey K. Anders, Laura Testa, Hans Wildiers, Ling-Ming Tseng, Yen-Shen Lu, Yeon Hee Park, Seock-Ah Im, Shin-Cheh Chen, Robyn R. Young, Caron Lloyd, Magdalena Wrona, Cuihong Zhang, Danielle Carroll and Fabrice André
Other articles about Breast Cancer on OncoDaily.